{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:41:51Z","timestamp":1793943711903,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.bbmt.2016.11.010","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T03:18:10Z","timestamp":1479093490000},"page":"262-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7453-0045","authenticated-orcid":false,"given":"Dharshan","family":"Sivaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwynn D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson J.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.11.010_bib0010","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0015","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0025","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0030","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous hematopoietic stem-cell transplantation for multiple myeloma","volume":"360","author":"Harousseau","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/asheducation.V2013.1.496.3847117","article-title":"Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients","volume":"2013","author":"McCarthy","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0045","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V126.23.396.396","article-title":"Post-transplant therapy is more important than induction regimen choice in autologous hematopoietic cell transplantation (AHCT) recipients for multiple myeloma (MM)","volume":"126","author":"Cornell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0050","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0055","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0060","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","volume":"136","author":"Shustik","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0070","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0075","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with Adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0080","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ajh.23274","article-title":"Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma","volume":"87","author":"Maiolino","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0085","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0090","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0100","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0105","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0115","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0120","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0125","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1078155213514468","article-title":"Multiple myeloma maintenance therapy: a review of the pharmacologic treatment","volume":"21","author":"Shank","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11899-016-0310-9","article-title":"Consolidation and maintenance therapies for newly diagnosed multiple myeloma in the era of novel agents","volume":"11","author":"Nathwani","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"23","key":"10.1016\/j.bbmt.2016.11.010_bib0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V126.23.27.27","article-title":"Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65\/GMMG-HD4 trial","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0145","doi-asserted-by":"crossref","first-page":"e652395","DOI":"10.1155\/2014\/652395","article-title":"Post-autologous (ASCT) stem cell transplant therapy in multiple myeloma","volume":"2014","author":"Al-Mansour","year":"2014","journal-title":"Adv Hematol"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/DDDT.S93602","article-title":"Spotlight on ixazomib: potential in the treatment of multiple myeloma","author":"Azab","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"23","key":"10.1016\/j.bbmt.2016.11.010_bib0155","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood.V126.23.3155.3155","article-title":"Phase II study of the combination of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.11.010_bib0160","first-page":"15","article-title":"Profile of elotuzumab and its potential in the treatment of multiple myeloma","volume":"2014","author":"Liu","year":"2014","journal-title":"Blood Lymphat Cancer"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116304888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116304888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:44Z","timestamp":1761058664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116304888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1083879116304888"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.010","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}